ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Biosero, a laboratory automation systems firm, will collaborate with DeepCure, an artificial intelligence–enabled drug discovery company, on the development of a fully automated chemistry synthesis platform. The project, undertaken at DeepCure’s facility in Rehovot, Israel, will combine the firm’s AI discovery technology with a suite of Biosero automation software. By joining AI and automated workflows, the partners aim to advance a robotic chemistry platform enabling rapid and cost-effective chemical synthesis.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X